2-(1-(4-chlorophenyl)cyclopentyl)acetic acid | 1075189-99-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(1-(4-chlorophenyl)cyclopentyl)acetic acid
• 英文别名: 2-[1-(4-Chlorophenyl)cyclopentyl]acetic acid
• CAS: 1075189-99-9
• 化学式: C₁₃H₁₅ClO₂
• 分子量: 238.714
• InChiKey: JUQJQTGVVINASX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(1-(4-chlorophenyl)cyclopentyl)-2-cyanoacetic acid 在 氢氧化钾 、 乙二醇 、 盐酸 作用下， 以 水 、 乙二醇 为溶剂， 反应 4.0h， 生成 2-(1-(4-chlorophenyl)cyclopentyl)acetic acid
  参考文献：
  名称：

  WO2008/134693

  摘要：

  公开号：

文献信息

• Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder
  申请人：Bailey Andrew

  公开号：US20090233965A1

  公开（公告）日：2009-09-17

  The invention provides compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions and their use in therapy (I).

  本发明提供了公式（I）的化合物，其中R1，R2，R3，R4，R5和X如规范中所定义，以及它们的制备方法，包含它们的药物组合物，制备药物组合物的方法以及它们在治疗中的应用。
• Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme
  申请人：Judd Andrew S.

  公开号：US20080312282A1

  公开（公告）日：2008-12-18

  The present invention relates to compounds of formula (I): wherein Q, G 1 , G 2 , and G 3 , are defined herein. Pharmaceutical compositions and methods for treating DGAT- 1 related diseases or conditions are also disclosed.

  本发明涉及式(I)的化合物：其中Q，G1，G2和G3在此定义。还公开了用于治疗DGAT-1相关疾病或病状的药物组合物和方法。
• NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
  申请人：Pesyan Amir

  公开号：US20110046128A1

  公开（公告）日：2011-02-24

  A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.

  本文介绍了一系列新型化合物，具有抗惊厥、化学对抗剂和镇痛活性。这些药物活性化合物也可能在治疗其他中枢神经系统（“CNS”）疾病和障碍方面发挥作用，如焦虑、抑郁、失眠、偏头痛、精神分裂症、帕金森病、痉挛、阿尔茨海默病和双相情感障碍。此外，这些化合物还可以作为镇痛剂（例如，用于慢性或神经性疼痛的治疗）和作为神经保护剂，有助于治疗中风、慢性神经退行性疾病（如阿尔茨海默病和亨廷顿病）以及创伤性脑和/或脊髓损伤。此外，这些化合物还可以用于治疗癫痫持续状态和/或作为化学对抗剂。
• INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME
  申请人：Judd Andrew S.

  公开号：US20120277223A1

  公开（公告）日：2012-11-01

  The present invention relates to compounds of formula (I): wherein Q, G 1 , G 2 , and G 3 , are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

  本发明涉及式(I)的化合物：其中Q，G1，G2和G3在此被定义。还公开了治疗DGAT-1相关疾病或病况的药物组合物和方法。
• Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
  申请人：Abbott Laboratories

  公开号：EP2452937A1

  公开（公告）日：2012-05-16

  The present invention relates to compounds of formula (I): wherein Q, G1, G2, and G3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

  本发明涉及式（I）化合物：其中 Q、G1、G2 和 G3 在此定义。还公开了治疗 DGAT-1 相关疾病或病症的药物组合物和方法。